Oaktree Acquisition Corp. III Life Sciences(OACCW)Earnings, Financials & Key Ratios
OACCW•NASDAQ•Banking & Credit
15.1× P/E·Price updated Jun 19, 2026
SectorFinancial ServicesIndustrySPACs & Shell CompaniesSub-IndustryHealthcare and life sciences SPACs
AboutOaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was incorporated in 2024 and is based in Los Angeles, California.Show more
- Net Interest Income$2M
- Total Revenue$0
- Net Income$1M
- Return on Equity0.71%
- Net Interest Margin0.81%
- ROA0.68%
- Equity / Assets96.03%
- Book Value per Share7.63
OACCW Key Insights
Oaktree Acquisition Corp. III Life Sciences (OACCW) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Well capitalized: 96.0% equity/assets
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Weak 3Y average ROE of 0.7%
- ✗Weak NIM of 0.8%
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when OACCW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OACCW Price & Volume
Oaktree Acquisition Corp. III Life Sciences (OACCW) stock price & volume — 10-year historical chart
Loading chart...
OACCW Growth Metrics
Oaktree Acquisition Corp. III Life Sciences (OACCW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-0.18%
5 Years-0.18%
3 Years-0.18%
Last Year-0.18%
OACCW Peer Comparison
Oaktree Acquisition Corp. III Life Sciences (OACCW) competitors in Healthcare and life sciences SPACs — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RLAY | 3B | 15.88 | -9.86 | 53.44% | -25.54% | -43.94% | 0.06 | |
 RXRX | 1.44B | 3.23 | -2.24 | 26.92% | -8.44% | -54.32% | 0.07 | |
 BCTX | 5.46M | 2.90 | -0.05 | -172.45% | ||||
 IPOD | 151.2M | 10.44 | 47.45 | 18.18% | ||||
 BX | 96.99B | 123.78 | 31.90 | 21.58% | 21.83% | 14.35% | 0.61 | |
 KKR | 86.49B | 97.01 | 41.46 | -10.99% | 12.45% | 3.19% | 0.67 | |
 APO | 79.27B | 137.50 | 18.94 | 16.03% | 7.24% | 5.52% | 0.31 | |
 CG | 16.18B | 44.80 | 20.55 | 19.8% | 13.7% | 7.81% | 1.97 |
Compare OACCW vs Peers
Oaktree Acquisition Corp. III Life Sciences (OACCW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OACCW Income Statement
Oaktree Acquisition Corp. III Life Sciences (OACCW) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'24 | TTM |
|---|---|---|
Net Interest Income | 1.59M | 5.93M |
NII Growth % | - | 0% |
Net Interest Margin % | 0.81% | 2.94% |
Interest Income | 1.59M | 5.93M |
Interest Expense | 0 | 0 |
Loan Loss Provision | 0 | 0 |
Non-Interest Income | -1.59M | -5.93M |
Non-Interest Income % | - | - |
Total Revenue | 0▲ 0% | 0▲ 0% |
Revenue Growth % | - | 0% |
Non-Interest Expense | 351.81K | 799.1K |
Efficiency Ratio | - | - |
Operating Income | -351.81K▲ 0% | -799.1K▲ 0% |
Operating Margin % | - | - |
Operating Income Growth % | - | - |
Pretax Income | 1.33M▲ 0% | 5.22M▲ 0% |
Pretax Margin % | - | - |
Income Tax | 0 | 0 |
Effective Tax Rate % | 0% | 0% |
Net Income | 1.33M▲ 0% | 5.22M▲ 0% |
Net Margin % | - | - |
Net Income Growth % | - | - |
Net Income (Continuing) | 1.33M | 5.22M |
EPS (Diluted) | 0.05▲ 0% | -▲ 0% |
EPS Growth % | - | - |
EPS (Basic) | 0.05 | - |
Diluted Shares Outstanding | 24.58M | 19.2M |
OACCW Balance Sheet
Oaktree Acquisition Corp. III Life Sciences (OACCW) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'24 | TTM |
|---|---|---|
Cash & Short Term Investments | 1.36M | 4.07M |
Cash & Due from Banks | 1.36M | 1.33M |
Short Term Investments | 0 | 0 |
Total Investments | 193.58M | 199.77M |
Investments Growth % | - | 0% |
Long-Term Investments | 193.58M | 590.92M |
Accounts Receivables | 0 | 0 |
Goodwill & Intangibles | 0 | 0 |
Goodwill | 0 | 0 |
Intangible Assets | 0 | 0 |
PP&E (Net) | 0 | 0 |
Other Assets | 113.28K | 0 |
Total Current Assets | 1.56M | 1.48M |
Total Non-Current Assets | 193.69M | 199.77M |
Total Assets | 195.25M▲ 0% | 201.25M▲ 0% |
Asset Growth % | - | 0% |
Return on Assets (ROA) | 0.68% | 2.63% |
Accounts Payable | 0 | 414.11K |
Total Debt | 11.82K | 11.82K |
Net Debt | -1.35M | -1.32M |
Long-Term Debt | 0 | 0 |
Short-Term Debt | 11.82K | 11.82K |
Other Liabilities | 7.02M | 6.72M |
Total Current Liabilities | 727.32K | 1.23M |
Total Non-Current Liabilities | 7.02M | 7.02M |
Total Liabilities | 7.75M | 8.25M |
Total Equity | 187.5M▲ 0% | 193M▲ 0% |
Equity Growth % | - | 0% |
Equity / Assets (Capital Ratio) | 96.03% | 95.9% |
Return on Equity (ROE) | 0.71% | 2.74% |
Book Value per Share | 7.63 | 10.05 |
Tangible BV per Share | 7.63 | 10.05 |
Common Stock | 193.58M | 199.77M |
Additional Paid-in Capital | 0 | 0 |
Retained Earnings | -6.08M | -6.77M |
Accumulated OCI | 0 | 0 |
Treasury Stock | 0 | 0 |
Preferred Stock | 0 | 0 |
OACCW Cash Flow Statement
Oaktree Acquisition Corp. III Life Sciences (OACCW) cash flow — operating, investing & free cash flow history
| Metric | Dec'24 | TTM |
|---|---|---|
Cash from Operations | -89.69K | -278.2K |
Operating CF Growth % | - | 0% |
Net Income | 1.33M | 5.5M |
Depreciation & Amortization | 0 | 0 |
Deferred Taxes | 0 | 0 |
Other Non-Cash Items | -1.64M | -5.78M |
Working Capital Changes | 220.96K | 0 |
Cash from Investing | -191.99M | 250K |
Purchase of Investments | -191.99M | 0 |
Sale/Maturity of Investments | 0 | 0 |
Net Investment Activity | -191.99M | 0 |
Acquisitions | 0 | 0 |
Other Investing | 0 | 250K |
Cash from Financing | 193.44M | 0 |
Dividends Paid | 0 | -8.5M |
Share Repurchases | 0 | 0 |
Stock Issued | 193.99M | 0 |
Net Stock Activity | 193.99M | 0 |
Debt Issuance (Net) | -551.14K | -551.14K |
Other Financing | 0 | -184.94M |
Net Change in Cash | 1.36M▲ 0% | 1.33M▲ 0% |
Exchange Rate Effect | 0 | 0 |
Cash at Beginning | 0 | 1.39M |
Cash at End | 1.36M | 1.33M |
Interest Paid | 0 | 0 |
Income Taxes Paid | 0 | 0 |
Free Cash Flow | -89.69K▲ 0% | -278.2K▲ 0% |
FCF Growth % | - | - |
OACCW Banking Ratios
Oaktree Acquisition Corp. III Life Sciences (OACCW) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | TTM |
|---|---|
Return on Equity (ROE) | 2.74% |
Return on Assets (ROA) | 2.63% |
Net Interest Margin | 2.94% |
Equity / Assets | 95.9% |
Book Value / Share | 10.05 |
Dividend Payout | 81.36% |
Related:OACCW Dividend History·OACCW Revenue History·OACCW Price History·OACCW P/E History·OACCW Financial Ratios·OACCW Institutional Holders
OACCW Frequently Asked Questions
Oaktree Acquisition Corp. III Life Sciences (OACCW) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Oaktree Acquisition Corp. III Life Sciences (OACCW) grew revenue by 0.0% over the past year. Growth has been modest.
Yes, Oaktree Acquisition Corp. III Life Sciences (OACCW) is profitable, generating $1.3M in net income for fiscal year 2024.
Dividend & Returns
Oaktree Acquisition Corp. III Life Sciences (OACCW) has a return on equity (ROE) of 0.7%. This is below average, suggesting room for improvement.
Industry Metrics
Oaktree Acquisition Corp. III Life Sciences (OACCW) has a net interest margin (NIM) of 0.8%. NIM has been under pressure due to interest rate environment.
Oaktree Acquisition Corp. III Life Sciences (OACCW) has an efficiency ratio of 0.0%. This is excellent, indicating strong cost control.